8-K filed Jul 2, 2026 at 17:01 ET
Iovance Biotherapeutics filed an 8-K to update its corporate presentation, which is a routine administrative event. The presentation reiterates previously disclosed financial guidance (FY26 revenue $350M-$370M, Q2 2026 revenue $86M-$88M) and pipeline progress, including the TILVANCE-301 Phase 3 frontline melanoma trial and IOV-LUN-202 NSCLC registrational trial. No new material financial data or business developments were disclosed beyond what was already public.